BrainScores

BrainScores operates at the intersection of AI software, medical imaging, epilepsy diagnostics, and surgical planning. Its stated focus is narrower than broad radiology-AI platforms: the product targets drug-resistant epilepsy and the detection of subtle cortical and subcortical abnormalities that may be overlooked in conventional review. The company differentiates through whole-brain morphometric mapping, quantitative cortical deviation analysis, multimodal MRI harmonization, and expert radiologist validation rather than relying only on an opaque classification output. Its workflow also extends beyond diagnosis by exporting results to neuronavigation systems from Medtronic, ROSA, Brainlab, and Zimmer Biomet. Relative to general-purpose medical imaging AI vendors, BrainScores appears specialized around epilepsy presurgical workflows and multidisciplinary review. Its competitive challenge is likely clinical adoption: demonstrating reproducible performance across scanners, protocols, hospitals, and patient populations while fitting existing radiology and surgical processes. Public information does not establish regulatory clearances, commercial scale, or comparative clinical outcomes.

BrainScores shows a product-led trajectory built around progressively connecting several stages of epilepsy care: MRI quality control and standardization, whole-brain quantitative mapping, AI-assisted lesion identification, validated reporting, and surgical-navigation export. This integrated scope suggests an attempt to become workflow infrastructure rather than a single-point imaging algorithm. The company’s stated ability to support almost any MRI scanner or protocol is another potential scaling lever because it can reduce dependence on a particular imaging configuration. The company is categorized in the 1–10 employee range, indicating an early operating scale, but there is insufficient evidence to determine whether that represents growth or a stable team size. Its Montreal location and links to epilepsy imaging research provide a credible development context, while integrations with major neuronavigation platforms could support expansion into surgical workflows. The clearest inflection point is the shift from research-oriented imaging analysis toward a collaborative clinical platform, although commercialization and adoption milestones remain unverified as of Oct 7, 2026.